Effects of Cerebellar Transcranial Magnetic Stimulation on Ataxias: A Randomized Trial
Overview
Authors
Affiliations
Introduction: Cerebellar ataxia remains a neurological symptom orphan of treatment interventions, despite being prevalent and incapacitating. We aimed to study, in a double-blind design, whether cerebellar modulation could improve ataxia.
Methods: We included patients with diagnosis of spinocerebellar ataxia type 3, multiple systems atrophy cerebellar type, or post-lesion ataxia. Patients received five sessions each of sham and active cerebellar 1 Hz deep repetitive transcranial magnetic stimulation in randomized order. Our primary outcome was the decrease in the Scale for the Assessment and Rating of Ataxia when comparing phases (active x sham). Secondary outcomes measures included the International Cooperative Ataxia Rating Scale, and other motor, cognitive, and quality of life scales. This study was registered at clinicaltrials.gov (protocol NCT03213106).
Results: Twenty-four patients aged 29-74 years were included in our trial. After active stimulation, the Scale for the Assessment and Rating of Ataxia score was significantly lower than the score after sham stimulation [median (interquartile range) of 10.2 (6.2, 16.2) versus 12.8 (9.6, 17.8); p = 0.002]. The International Cooperative Ataxia Rating Scale score also improved after active stimulation versus sham [median (interquartile range) of 29.0 (21.0, 43.5) versus 32.8 (22.0, 47.0); p = 0.005]. Other secondary outcomes were not significantly modified by stimulation. No patient presented severe side effects, and nine presented mild and self-limited symptoms.
Conclusions: Our protocol was safe and well-tolerated. These findings suggest that cerebellar modulation may improve ataxic symptom and provide reassurance about safety for clinical practice.
Matsugi A, Ohtsuka H, Bando K, Kondo Y, Kikuchi Y Mov Disord Clin Pract. 2024; 11(11):1323-1334.
PMID: 39221650 PMC: 11542298. DOI: 10.1002/mdc3.14205.
Grobe-Einsler M, Bork F, Faikus A, Hurlemann R, Kaut O CNS Neurosci Ther. 2024; 30(6):e14797.
PMID: 38887169 PMC: 11183922. DOI: 10.1111/cns.14797.
Clinical neurophysiology in the treatment of movement disorders: IFCN handbook chapter.
Lefaucheur J, Moro E, Shirota Y, Ugawa Y, Grippe T, Chen R Clin Neurophysiol. 2024; 164:57-99.
PMID: 38852434 PMC: 11418354. DOI: 10.1016/j.clinph.2024.05.007.
Hamdan A, Hooker A, Chen X, Traschutz A, Schule R, Synofzik M CPT Pharmacometrics Syst Pharmacol. 2024; 13(8):1327-1340.
PMID: 38769902 PMC: 11330187. DOI: 10.1002/psp4.13162.
Potashman M, Rudell K, Pavisic I, Suminski N, Doma R, Heinrich M Cerebellum. 2024; 23(5):2012-2027.
PMID: 38713312 PMC: 11489265. DOI: 10.1007/s12311-024-01700-2.